Opinion and Comment

CASE STUDY:孤立するミリアド社

Nature Biotechnology 32, 7 doi: 10.1038/nbt.2944

Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.

目次へ戻る

プライバシーマーク制度